With 2 very favorable judges then our odds may come around to 60-65% IMO and we won’t know that until the day of oral arguments.
Your email to JT is further enabling management agenda of ‘how can I get really rich‘. These asses had an opportunity to settle with both Hikma and Ready...they flat out refused! Can I prove they refused? Absolutely....no deal was made! Management could have offered an earlier entry into R-I as bait....they failed...or refused...either way incompetence is the only defining word that accurately describes the lack of settlement.
Management had a bonus scheduled to include protection of IP...? Unclear at this moment, but that’s something I want answered!
I love Vascepa but hate Amarin! Management is absolutely incompetent and that includes JT letting Kennedy drive “strategy”; only mistake after mistake following refusal to litigate ACHOR SPA rescindment. AMARIN was ONLY toting big pharmaceutical First Amendment agenda!!! Only reasons why they didn’t protect AMRN longs, sucking up to BP agenda and attempting to enrich themselves in a clean IP win!
Mistake after mistake...an appeal win odds is less than 25%! Facts are diluted by Judge Du decision and her appeal record of less than 10% reversal.
Great post. Only thing I disagree on is partnering in EU. They either win appeal and sell whole thing or lose appeal and sell Europe. Partnering is a ploy.
Thanks for sharing and hang in there. EU is worth $15, minimum.
Thank you for sharing, took a lot of courage, for what is worth, you are not alone. To show my respect to you, I won’t say anything bad here about mgmt, but really, that SOB didn’t reply to you at all?
Although I appreciate your heartfelt post I don't want to go down with the ship. If an equitable deal can be made for Europe or a not so equitable deal for Europe but with a CVR for the U.S. market then swallow your pride and accept it. Negotiating a deal holding the bag after an appeal loss would be like swimming in shark infested waters.
Publicly Amarin's plan is then to compete with the generics with their own generic Vascepa in the U.S. and have partnerships in Europe. That sounds like a nightmare within a nightmare.